Reuters logo
BRIEF-Aduro Biotech ‍announces data from preclinical studies with ADU-1604
November 10, 2017 / 1:19 PM / 9 days ago

BRIEF-Aduro Biotech ‍announces data from preclinical studies with ADU-1604

Nov 10 (Reuters) - Aduro Biotech Inc

* Aduro Biotech Inc - ‍announced data from preclinical studies with ADU-1604, company’s humanized anti-CTLA-4 monoclonal antibody​

* Aduro Biotech - ‍data from studies demonstrate potency of ADU-1604 and ability to inhibit tumor growth, enhance T cell-dependent antibody responses​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below